The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
Menopause was not found to drive disease progression in multiple sclerosis (MS) in women at midlife. Results from the longitudinal cohort study were published in JAMA Neurology.
Menopause was not found to drive disease progression in multiple sclerosis (MS) in women at midlife. Results from the longitudinal cohort study were published in JAMA Neurology.
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
The presence of frontal release signs (FRS), primitive reflexes that reemerge with neurodegeneration or brain injury, may help identify older adults at increased risk for future cognitive decline, according to a cohort study.
The presence of frontal release signs (FRS), primitive reflexes that reemerge with neurodegeneration or brain injury, may help identify older adults at increased risk for future cognitive decline, according to a cohort study.
A multicenter randomized clinical trial found that reperfusion-guided systolic blood pressure (BP) management after successful endovascular therapy improved 90-day functional outcomes compared with guideline-recommended care.
A multicenter randomized clinical trial found that reperfusion-guided systolic blood pressure (BP) management after successful endovascular therapy improved 90-day functional outcomes compared with guideline-recommended care.
SKY-0515, an investigational oral RNA splicing modifier, reduced mutant huntingtin (mHTT) protein levels in blood by up to 69% and PMS1 mRNA by up to 26% in a phase 1/2 Huntington’s disease (HD) trial.
SKY-0515, an investigational oral RNA splicing modifier, reduced mutant huntingtin (mHTT) protein levels in blood by up to 69% and PMS1 mRNA by up to 26% in a phase 1/2 Huntington’s disease (HD) trial.
In a South Korea–based multicenter cohort, plasma phosphorylated tau217 (p-tau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) were associated with cognitive decline in early-onset Alzheimer disease (EOAD).
In a South Korea–based multicenter cohort, plasma phosphorylated tau217 (p-tau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) were associated with cognitive decline in early-onset Alzheimer disease (EOAD).
Findings from a large Aspirin in Reducing Events in the Elderly (ASPREE) cohort suggest cognitive changes could serve as early indicators of cardiovascular risk.
Findings from a large Aspirin in Reducing Events in the Elderly (ASPREE) cohort suggest cognitive changes could serve as early indicators of cardiovascular risk.
The addition of endovascular treatment (EVT) to best medical treatment (BMT) was associated with a higher likelihood of achieving good imaging outcomes compared with BMT alone in patients with a medium or distal vessel occlusion stroke.
The addition of endovascular treatment (EVT) to best medical treatment (BMT) was associated with a higher likelihood of achieving good imaging outcomes compared with BMT alone in patients with a medium or distal vessel occlusion stroke.
Real-world data presented at the American Academy of Neurology (AAN) 2026 Annual Meeting reported improvements in migraine-related cognitive symptoms with eptinezumab (VYEPTI).
Real-world data presented at the American Academy of Neurology (AAN) 2026 Annual Meeting reported improvements in migraine-related cognitive symptoms with eptinezumab (VYEPTI).
Teleneurological ward rounds were found noninferior to conventional on-site ward rounds in subacute inpatient stroke care, according to prospective study findings.
Teleneurological ward rounds were found noninferior to conventional on-site ward rounds in subacute inpatient stroke care, according to prospective study findings.
High-dose influenza vaccination may confer additional neuroprotective benefit beyond standard-dose formulations, according to results from a new, large retrospective cohort study published in Neurology.
High-dose influenza vaccination may confer additional neuroprotective benefit beyond standard-dose formulations, according to results from a new, large retrospective cohort study published in Neurology.
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click